• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Cereno Scientific: Strategic financing strengthens partnering position - Edison

CRNO BThird party research01.07.2026, 15.04

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
Cereno Scientific has reported a SEK60m capital raise through a directed share issue of c 11.8m new B-shares at SEK5.10/share. Notably, the financing was concluded at a 4.1% premium to the previous closing price (SEK4.9) and without any attached warrants, reflecting strong investor support. The relatively modest size of the raise (c 3–4 months of operating cash per our estimates) suggests that the financing is strategic rather than purely runway driven. We believe management’s objective was to strengthen its balance sheet ahead of a strategically important period, including the planned initiation of the Phase IIb PAH study, while enhancing its negotiating leverage as partnering discussions gather momentum, following the strong interest reported at the BIO International Convention. Combining the end-Q126 gross cash balance of SEK70.9m with these latest proceeds, we estimate that the company now has operating headroom into Q127. We will update our forecasts and valuation to reflect the financing in due course.